ClinicalTrials.gov record
Completed Phase 3 Interventional

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

ClinicalTrials.gov ID: NCT05517421

Public ClinicalTrials.gov record NCT05517421. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)

Study identification

NCT ID
NCT05517421
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Immunovant Sciences GmbH
Industry
Enrollment
114 participants

Conditions and interventions

Interventions

  • Batoclimab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 22, 2022
Primary completion
Nov 1, 2025
Completion
Nov 17, 2025
Last update posted
Dec 2, 2025

2022 – 2025

United States locations

U.S. sites
29
U.S. states
17
U.S. cities
27
Facility City State ZIP Site status
Site Number - 1557 Beverly Hills California 90210
Site Number - 1539 Carlsbad California 92011
Site Number - 1502 Los Angeles California 90025
Site Number - 1505 Los Angeles California 90033
Site Number - 1532 Los Angeles California 90255
Site Number - 1537 San Diego California 92108
Site Number - 1531 Torrance California 90505
Site Number - 1501 Aurora Colorado 80045
Site Number - 1544 Longmont Colorado 80503
Site Number - 1547 Newark Delaware 19713
Site Number - 1504 Miami Florida 33136
Site Number - 1538 Port Charlotte Florida 33952
Site Number - 1542 Tampa Florida 33603
Site Number - 1536 West Palm Beach Florida 33401
Site Number - 1554 Stockbridge Georgia 30281
Site Number - 1534 Chicago Illinois 60610
Site Number - 1545 Iowa City Iowa 52242
Site Number - 1535 Baltimore Maryland 21231
Site Number - 1506 Boston Massachusetts 02130
Site Number - 1540 Las Vegas Nevada 89184
Site Number - 1530 Chapel Hill North Carolina 27517
Site Number - 1550 Columbus Ohio 43215
Site Number - 1507 Portland Oregon 97232
Site Number - 1556 Warwick Rhode Island 02886
Site Number - 1551 Dallas Texas 75231
Site Number - 1508 Houston Texas 77030
Site Number - 1558 Mesquite Texas 75149
Site Number - 1500 Roanoke Virginia 24018
Site Number - 1509 Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05517421, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 2, 2025 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05517421 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →